Search

Your search keyword '"Roderburg, C."' showing total 369 results
Start Over Author "Roderburg, C."
369 results on '"Roderburg, C."'

2. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art

Author

Laschtowitz A, Roderburg C, Tacke F, and Mohr R

Subjects
hepatocellular carcinoma, immune oncology, checkpoint inhibitor, neoadjuvant, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Alena Laschtowitz,1 Christoph Roderburg,2 Frank Tacke,1 Raphael Mohr1 1Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany; 2Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, GermanyCorrespondence: Raphael Mohr, Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, 13353, Germany, Email raphael.mohr@charite.deAbstract: Hepatocellular carcinoma (HCC) is a malignancy that requires multidisciplinary evaluation to develop individualized and tailored treatment concepts. While liver resection and transplantation represent the mainstay of curative treatment in patients with early-stage HCC, disease recurrence remains an important burden. Immune checkpoint inhibitors (ICI) have become standard of care in the palliative setting, achieving promising response rates with overall good tolerability. Accordingly, ICIs are being evaluated in (neo)adjuvant concepts in order to improve survival. Nevertheless, neoadjuvant therapies are not recommended by current guidelines as they have not been proven to improve the outcome in large Phase III trials yet. Especially in the context of liver transplantation (LT), perioperative ICI usage is in need of a particularly critical risk–benefit assessment, as the immunotherapy may significantly increase the risk of rejection. In this review, we summarize available data on ICI-based perioperative treatment strategies in HCC. We discuss current drawbacks and challenges of this treatment concept and specifically highlight the risk of allograft rejection when ICI are given in patients (subsequently) considered for liver transplantation.Keywords: hepatocellular carcinoma, immune oncology, checkpoint inhibitor, neoadjuvant

Published
2023

3. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

Author

Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. Fischer, Dechow, T., Kaiser, F., Karthaus, M., Schwaner, I., Fuchs, M., König, A., Roderburg, C., Hoyer, I., Quante, M., Kiani, A., Fruehauf, S., Müller, L., Reinacher-Schick, A., Ettrich, T. J., Stahler, A., and Modest, D. P.

Published
2022
Full Text
View/download PDF

6. LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

Author

Kasper-Virchow, S., Hofheinz, R.D., Stintzing, S., Dechow, T.N., Ettrich, T.J., Sinn, M., Roderburg, C., Fischer von Weikersthal, L., Graeven, U., Mueller, C., Meiler, J., Stein, A., Modest, D.P., Pauligk, C., Virchow, I., Siveke, J.T., Al-Batran, S-E., Schuler, M.H.H., and Goetze, T.O.

Published
2024
Full Text
View/download PDF

9. Additional file 1 of Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

Author

Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. Fischer, Dechow, T., Kaiser, F., Karthaus, M., Schwaner, I., Fuchs, M., König, A., Roderburg, C., Hoyer, I., Quante, M., Kiani, A., Fruehauf, S., Müller, L., Reinacher-Schick, A., Ettrich, T. J., Stahler, A., and Modest, D. P.

Abstract

Additional file 1. Schedule of Study Assessments for the FIRE-8 trial.

Published
2022
Full Text
View/download PDF

10. Randomized Clinical Trial: Perioperative Rifaximin Is Not Associated with Enhanced Functional and Volumetric Recovery after Major Liver Resection (ARROW)

Author

Bednarsch, J., primary, Czigany, Z., additional, Loosen, S.H., additional, Heij, L.R., additional, Ruckgaber, L., additional, Maes, H., additional, Krause, J.-P., additional, Reen, M., additional, Toteva, B., additional, Vosdellen, T., additional, Bruners, P., additional, Lang, S.A., additional, Ulmer, T.F., additional, Roderburg, C., additional, Luedde, T., additional, and Neumann, U.P., additional

Published
2022
Full Text
View/download PDF

11. Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases

Author

Loosen, S.H., Roderburg, C., Alizai, P.H., Roeth, A.A., Schmitz, S.M., Vucur, M., Luedde, M., Schoeler, D., Paffenholz, P., Tacke, F., Trautwein, C., Luedde, T., Neumann, U.P., Ulmer, T.F., Surgery, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
SURGERY, IMPACT, HEPATIC RESECTION, CRLM, CA19-9, TUMOR-MARKERS, GUIDELINES, survival, CANCER, CRC, CEA, STAGE, liver resection, CRP, PROGRESS, METAANALYSIS
Abstract

Surgical tumor resection has evolved as a potentially curative therapy for patients with resectable colorectal liver metastases (CRLM). However, disease recurrence is common and the available preoperative stratification strategies are often imprecise to identify the ideal candidates for surgical treatment, resulting in a postoperative 5-year survival rate below 50%. Data on the prognostic value of CEA, CA19-9 and other common laboratory parameters after CRLM resection are scarce and partly inconclusive. Here, we analyzed the prognostic potential of circulating CEA and CA19-9 in comparison to other standard laboratory markers in resectable CRLM patients. Serum levels of tumor markers and other laboratory parameters were analyzed in 125 patients with CRLM undergoing tumor resection at a tertiary referral center. Results were correlated with clinical data and outcome. Both tumor markers were significantly elevated in CRLM patients compared to healthy controls. Interestingly, elevated levels of CEA, CA19-9 and C-reactive protein (CRP) were associated with an unfavorable prognosis after CRLM resection in Kaplan-Meier curve analysis. However, only CEA and not CA19-9 or CRP serum levels were an independent prognostic marker in multivariate Cox regression analysis. Our data demonstrate that circulating levels of CEA rather than CA19-9 might be a valuable addition to the existing preoperative stratification algorithms to identify patients with a poor prognosis after CRLM resection.

Published
2021

17. Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany

Author

Jacob L, Loosen SH, Kalder M, Luedde T, Roderburg C, and Kostev K

Subjects
specialized practices, general practices, Germany, cancer diagnosis, COVID-19 pandemic
Abstract

The aim of this retrospective study was to investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on cancer diagnosis in general and specialized practices in Germany. This study included a total of 102,009 patients aged =18 years newly diagnosed with cancer in 1660 practices in Germany from January to May 2019 and from January to May 2020. Practices included general, gynecology, ear, nose, and throat (ENT), dermatology, and urology practices. New cancer diagnoses included all types of cancer and corresponded to cancers not previously documented in the database for a given patient. The number of new cancer diagnoses per general practice decreased significantly between March and May 2020 compared with the same period in 2019 (March: -12.0%, April: -27.6%, and May: -23.4%). A similar trend was observed in specialized practices, and this trend was more pronounced in April 2020 (dermatology: -44.4%, gynecology: -32.0%, and ENT: -28.2%). In addition, there was a significant decrease in almost all sex and age groups in April and May 2020 compared with the same period in 2019. Finally, the decrease in the number of new cancer diagnoses was particularly pronounced among cancers of the skin and the respiratory and intrathoracic organs. Together, these data show that the COVID-19 pandemic had a significant negative impact on cancer diagnosis in Germany, highlighting the need for public health measures improving the management of cancer in this country during this ongoing pandemic.

Published
2021

27. miR-193a-5 p regulates NUSAP1 expression to suppress hepatocarcinogenesis

Author

Roy, S, additional, Hooiveld, GJ, additional, Seehawer, M, additional, Caruso, S, additional, Pikarsky, E, additional, Tacke, F, additional, Vucur, M, additional, Kather, JN, additional, Zucman-Rossi, J, additional, Trautwein, C, additional, Zender, L, additional, Heikenwälder, M, additional, Roderburg, C, additional, and Luedde, T, additional

Published
2019
Full Text
View/download PDF

34. RIPK1 suppresses a TRAF2-dependent pathway to liver cancer

Author

Schneider, A.T., primary, Gautheron, J., additional, Feoktistova, M., additional, Roderburg, C., additional, Loosen, S.H., additional, Schemmer, P., additional, Büchler, M.W., additional, Neumann, U.P., additional, Tacke, F., additional, Trautwein, C., additional, Longerich, T., additional, Vucur, M., additional, and Luedde, T., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results